H Lundbeck A/S

H Lundbeck A/S EBIT per Share

The EBIT per Share of H Lundbeck A/S (LUN.CO) as of Oct 26, 2026 is 6.39 DKK. In the previous year, EBIT per Share was 3.30 DKK — a change of 93.80% (higher).

EBIT per Share

6.39DKK

YoY

93.80%

Last updated:

EBIT per Share of H Lundbeck A/S is 2025 6.39 DKK. EBIT per Share of H Lundbeck A/S was 2024 3.30 DKK. It decreases by 93.80% higher compared to the previous year.

The H Lundbeck A/S EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2019
18.15 DKK
Jan 1, 2020
10.02 DKK
Jan 1, 2021
10.12 DKK
Jan 1, 2022
14.35 DKK
Jan 1, 2023
3.22 DKK
Jan 1, 2024
3.30 DKK
Jan 1, 2025
6.39 DKK
Jan 1, 2026 (e)
8.66 DKK
The H Lundbeck A/S EBIT per Share history
YEAREBIT per ShareYoY
est8.66DKK+35.43%
6.39DKK+93.80%
3.30DKK+2.45%
3.22DKK-77.57%
14.35DKK+41.89%
10.12DKK+1.01%
10.02DKK-44.82%
18.15DKK-31.97%
26.68DKK+20.26%
22.18DKK+91.16%
11.61DKK-135.11%
-33.05DKK-6,657.21%
0.50DKK-93.81%
8.15DKK-3.01%
8.40DKK-51.46%
17.30DKK+1.07%
17.12DKK+17.43%
14.58DKK+510.11%
2.39DKK-9.14%
2.63DKK+55.59%
1.69DKK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

H Lundbeck A/S Stock analysis

What does H Lundbeck A/S do? H Lundbeck A/S is a Danish company that was founded in 1915 by Hans Lundbeck. Since its inception, the company has focused on researching and developing medications that improve the lives of people with neuropsychiatric disorders. Lundbeck's business model is based on a clear strategy and a strong focus on the research and development of pharmaceuticals. The company has four main therapy areas: depression, anxiety disorders, Alzheimer's, and Parkinson's. Lundbeck products are sold in over 100 countries worldwide and are known for their effectiveness and high quality. Over the years, Lundbeck has also focused on developing innovative treatment methods, including research on new drugs and therapies based on neurotransmitters such as serotonin, dopamine, and norepinephrine. With the acquisition of Alder BioPharmaceuticals in 2019, Lundbeck also expanded its portfolio in the field of migraine therapy. Some of Lundbeck's most well-known products include Lexapro, Cipralex, Selincro, Abilify Maintena, and Brintellix. These medications are used in the treatment of depression, anxiety disorders, alcoholism, bipolar disorders, and migraines. In addition to selling medications, Lundbeck also provides training and support for healthcare professionals and patients. Lundbeck is also distinguished by its commitment to social engagement and works closely with nonprofit organizations to raise awareness of neuropsychiatric disorders. The company has also launched various programs to improve access to medical care in particularly affected regions. In 2020, Lundbeck exceeded 18,000 employees worldwide and had a revenue of 16.6 billion Danish kroner. Lundbeck is listed on NASDAQ OMX Copenhagen and is controlled by the Lundbeck Foundation, which holds over 70% of the company's ownership. In summary, Lundbeck is a leading company in the field of neuropsychiatric medicine and is dedicated to improving the lives of people with these serious disorders. The company has made a name for itself through its successful research and development of therapies and medications, as well as its strong focus on social engagement and corporate social responsibility. H Lundbeck A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about H Lundbeck A/S stock

EBIT per Share of H Lundbeck A/S is 6.39 DKK in 2025.

EBIT per Share of H Lundbeck A/S changed from 3.30 DKK to 6.39 DKK, representing a 93.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share H Lundbeck A/S since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — H Lundbeck A/S

All Key Metrics — H Lundbeck A/S